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ABBREVIATIONS 
ACE     Angiotensin converting enzyme 
ARB     Angiotensin receptor blocker 
CPGN   Chronic primary glomerulonephritides 
CI          Confidence interval
CKD     Chronic kidney disease 
eGFR     estimated Glomerular filtration rate 
ESRD    End stage renal disease 
FSGS     Focal and segmental glomerulosclerosis 
GFR      Glomerular filtration rate 
HLA      Human leukocyte antigens 
HR         Hazard ratio 
IgAN     Immunoglobulin A nephropathy 
KM        Kaplan Meier 
LRD       Living related donor 
MDRD  Modification of diet in renal disease 
MN        Membranous nephropathy 
PLA2R  Phospholipase A2 receptor 
PRA       Panel reactive antibodies 
RP          Rapid progressive 
SIR         Standardized incidence ratio 
SP           Slow progressive 
UD          Unrelated donor 
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INTRODUCTION 
Chronic primary glomerulonephritides (CPGN) is a group of diseases characterised by 
leakage of proteins and/or erythrocytes into the urine with or without decreased glomerular 
filtration rate (GFR), hypertension, oedema, hyperlipidemia and low serum albumin. 
Although CPGN often are benign conditions, there is an increased risk for development of 
end-stage renal disease (ESRD), a complication that sometimes can be avoided by using 
potent, but toxic, immunosuppressive drugs [1]. Patients who develop ESRD need dialysis or 
kidney transplantation for further survival. However, these treatments are expensive and 
associated with decreased quality of life and increased mortality risk. Even after having 
caused destruction of the native kidneys, CPGN may recur in a transplanted kidney and thus 
cause failure also of this kidney [2]. As the outcomes of patients with CPGN are varied and 
the treatment options often are toxic and dangerous, selection of patients for appropriate 
treatment and follow-up regimens is of major importance. A correct histopathological 
diagnosis is mandatory, but in itself not sufficient, to decide the optimal treatment in 
individual patients. Within the various diagnoses of CPGN patients, the outcome with regard 
to risk of ESRD is varied and prognostic parameters are important for optimal treatment 
decisions. Thus, the study of prognostic factors and the combination of such factors as useful 
prognostic tools in the various types of CPGN is very important [3-6]. The number of patients 
with various types of CPGN are relatively low within each group of diseases. In addition,  
time from diagnosis of renal disease to ESRD may vary from weeks to decades, facts that 
complicate the study of prognostic factors in patients with such conditions.  
Although risk of ESRD is their major and most investigated hazard, CPGN patients are also at 
increased risk of other major clinical complications. One of which is an increased risk of 
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malignant tumors [7].  A complex and multicausal association between malignant diseases 
and CPGN is described. Malignant tumors may cause CPGN through immunological 
mechanisms [8], and immunosuppressive drugs used against CPGN increases long term risk 
of malignancies [9-11] and other unknown mechanisms may also contribute.  
The Norwegian Kidney Biopsy Registry was established in 1988 and its major goal was to 
study the epidemiology, aetiology, prognosis and treatment of patients with glomerular and 
other renal diseases. This registry has now become the largest active kidney biopsy registry in 
the world, containing information regarding more than 11000 kidney biopsies. The scientific 
value of the Norwegian Kidney Biopsy Registry is greatly enhanced by the linkage 
possibilities with other Norwegian medical and population registries such as the Norwegian 
Nephrology Registry (ESRD), the Norwegian Cancer Registry (cancer), the Norwegian 
Medical Birth Registry (births and pregnancy complications), the Norwegian Population 
Registry (survival), the Norwegian Cause of Death Registry, and others. Outcome data 
regarding patients in the Kidney Biopsy Registry can easily and reliably by collected through 
record linkage with the other registries using the unique 11 digit Norwegian person number. 
In the present doctoral thesis, the kidney biopsy registry has been linked to other registries 
and we were thus able to investigate long-term risk of cancer in membranous nephropathy as 
well as risk factors for ESRD and risk factors for graft failure after kidney transplantation in 
IgA nephropathy patients. 
In our studies we have focused on two different CPGN, membranous nephropathy (MN) and 
IgA nephropathy (IgAN). The characteristics of these conditions and the basis for our studies 
are described in the following section.    
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GLOMERULAR DISEASES STUDIED IN THE THESIS 
Membranous nephropathy 
MN is probably the most common cause of primary nephrotic syndrome in adult 
Caucasians and has a well-defined histological pattern characterised by deposition of 
subepithelial immune complexes in the glomerular basement membrane [12]. While the 
histological picture is similar, patients can clinically be divided into idiopathic or 
secondary MN.  
 
Idiopathic disease typically accounts for 70-90 % of MN cases.  A few years ago, auto-
antibodies against phospholipase A2 receptor (PLA2R) was found in the majority, but not 
all, idiopathic MN patients [13]. Several recent findings indicate that PLA2R auto-
antibodies might represent a causal mechanism in the development of MN, this is however 
not yet fully proven [14-18]. It is likely that we in the future will distinguish between 
PLA2R positive/negative idiopathic MN. Recently, two new types of auto-antibodies 
against podocyt membrane proteins in MN has been discovered, anti-aldose reductase and 
anti-manganese superoxide dismutase, the importance of these are still uncertain [19].    
 
Secondary MN has multiple aetiologies that cannot be identified by the routinely used 
morphological methods;  infections (hepatitis B/C, malaria and others), autoimmune 
diseases (systemic lupus erythematosus, rheumatoid arthritis, Sjøgrens syndrome, 
dermatomyositis, sarcoidosis and others), medication (gold, penicillamine, captopril, non-
steroidal antiinflamatory drugs and others), genetic and other rare causes. Malignancies 
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are usually also counted as a cause of secondary MN, this issue will be more thoroughly 
presented after this general introduction to MN. 
          
The most frequent presenting symptom in MN patients is nephrotic syndrome, most other 
patients present with less severe and often asymptomatic proteinuria. The natural course 
of MN is varied and depends on the aetiology and the clinical presentation. Spontaneous 
complete or partial remission is relatively common, also in untreated patients [20]. 
However, in cases with severe and long lasting proteinuria, development of ESRD is 
common, a complication that often can be prevented through use of various 
immunosuppressive drugs [21-24].  
 
MN patients are also at increased risk of thromboembolic complications, probably partly 
due to an altered balance between pro- and anticoagulant factors caused by urine protein 
losses [25]. An increased risk of infections is also observed and probably mediated 
through loss of protective antibodies in the urine and side-effects of immunosuppressive 
drugs.  
 
The initial therapeutic approach to MN patients is, if possible, to identify and remove the 
aetiological factor. This factor can however often not be identified.  The majority of MN 
patients are treated with angiotensin converting enzyme (ACE) inhibitors or angiotensin 
receptor blockers (ARB) and other antihypertensive agents [26]. Statins are often 
instituted against hyperlipidemia that often accompanies the nephrotic syndrome, their 
efficacy in protecting MN patients from cardiovascular complications is however not 
proven in clinical studies [27]. Some authors advocate the use of prophylactic 
anticoagulation in nephrotic MN patients, especially those with very low serum albumin 
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values, but this approach is controversial and not tested in randomized clinical studies 
[28]. In MN patients with very heavy proteinuria, especially if no sign of improvement 
during the first 6-12 months, and/or a tendency of decreasing eGFR, treatment with 
immunosuppressive drugs is indicated [5]. In the future, titres of antibodies towards 
PLA2R may also guide treatment [16], these analyses are not yet commercially available 
(August 2011). A number of immune modulating substances have proven effective in 
MN; steroids (but not in monotherapy), cyclophosphamide, chlorambucil, cycklosporin, 
tacrolimus and anti CD20 antibodies [21-24, 29-32]. The optimal drug regimen, both 
efficacy and toxicity taken into account, is not yet defined [1]. When MN patients develop 
ESRD, kidney transplantation is the preferred treatment modality [33-35]. MN may recur 
in the transplanted kidney but rarely causes graft loss [2]. 
 
Cancer and membranous nephropathy 
An increased risk of cancer in MN patients was first demonstrated by Lee and co-workers 
in 1966 [36], subsequently this association has been confirmed in a number of  studies 
[37-45]. There have also been studies that question the quantitative importance of the 
association between MN and cancer [37, 41]. It has been claimed that the co-occurrence 
of MN and cancer could be coincidental and caused by increased screening for cancer in 
MN patients.  
 
There are several theoretical immunological mechanisms that may explain how tumors 
might cause MN [8]. First, antibodies against tumor antigens could cross-react with 
podocyt antigens. Second, circulating tumor antigens could form circulating 
antigen/antibody complexes that are later trapped into the glomerular filtration barrier. 
Third, tumor antigens might get trapped in the glomerulus and later react with circulating 
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antibodies. Fourth, an extrinsic factor such as an oncogenic virus could cause both MN 
and cancer. The evidence in support of any of the above suggestive mechanisms has until 
recently been scarce. In a few, rather old, studies tumor antigens in glomerulus or 
antibodies directed against tumor antigens were demonstrated [46-50]. Some histological 
findings also indicate differences in pathophysiology between idiopathic and cancer 
associated MN. First, the dominant IgG class of the glomerular immunodeposits in 
idiopathic MN is IgG subclass 4 [51, 52] and in cancer associated MN are subclasses 1 
and 2 [53]. Second, an increased number of immune cells in the glomerulus have been 
observed in cancer associated as compared to idiopathic MN [42].  
 
Recently, it was demonstrated that in most cases of cancer associated MN, auto antibodies 
against PLA2R were not present [17]. This finding strongly suggests that idiopathic and 
cancer associated MN are different clinical conditions. That both PLA2R antibodies and 
cancer were present in a few cases indicate that the co-existence of both diseases was co-
incidental in such patients. 
 
In summary, the present bulk of evidence, particularly the new findings regarding PLA2R 
auto antibodies, strongly suggest that malignancy caused MN represents a true clinical 
entity. However, there may also be other mechanisms causing an increased risk of cancer 
among MN patients. Screening for cancer among MN patients could represent such a 
mechanism, but this effect should fade away during prolonged follow up after MN since 
most malignant tumors tend to become symptomatic over time. One should also not forget 
the possibility that the frequency of cancer associated MN in fact might be underestimated 
in biopsy series since many nephrologists will be reluctant to perform kidney biopsies in 
patients with advanced cancer and in cured cancer patients with MN, biopsies might be 
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considered unnecessary due to spontaneous remission of proteinuria after removal of the 
tumor.  
 
The frequent use of immunosuppressive drugs among MN patients might obviously cause 
an increased risk of cancer as in other patient groups treated with such drugs [10, 11].  
However, this mechanism can of course only explain an increased risk of malignant 
tumors occurring long time after the diagnosis of MN.  
 
The timing between diagnosis of MN and cancer is an issue of its own that naturally is of 
substantial clinical interest. Theoretically, rapidly growing tumors will be discovered early 
while small and slow growing tumors might persist undetected for a longer time while still 
causing immunological effects like MN. In the textbook literature, it is often claimed that 
the great majority of tumors associated with MN are detected prior to or simultaneously 
with the renal diagnosis and subsequently it is not necessary to look for causally related 
malignant tumors in the follow up period after MN. The bulk of evidence in support of 
this view is however far from impressive [8, 39, 40] and thus an investigation of this 
particular issue has been the aim of paper I in the present thesis.   
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IgA nephropathy 
IgA nephropathy (IgAN) is the most common glomerulonephritis in the world [54-56] and 
the characteristic morphological pattern is mesangial deposition of IgA and varying 
degrees of mesangial cell proliferation and expansion of mesangial matrix. The 
pathophysiological mechanism in IgAN is not fully understood but characterised by 
altered production and/or structure, reduced hepatic clearance and abnormal glycosylation 
of the IgA molecule [57]. As a result, IgA tend to deposit in the glomerular mesangium. 
Such depositions are indeed quite common in the general population and described in up 
to 16 % of assumed normal donor kidneys [58]. It seems as if only a subgroup of patients 
with mesangial IgA depositions develop glomerular inflammation, as characterized by cell 
proliferation and increased matrix production, and only a subgroup of these patients 
develop progressive fibrosis and loss of glomerular filtration rate (GFR). 
 
The classical presentations of IgAN are persistent asymptomatic hematuria and 
proteinuria or episodic macroscopic hematuria, often following an upper respiratory tract 
or gastrointestinal tract infection. Some IgAN patients also present with nephrotic or 
chronic nephritic syndrome.  
 
The long term prognosis of IgAN patiens is highly varied. Many IgAN patients can live 
several decades without signs of deteriorating kidney function, whereas others gradually 
experiences a decrease in GFR and develop ESRD [59]. Several prognostic factors at time 
of diagnosis in IgAN have been described, the most important ones are probably decline 
of GFR, level of proteinuria, hypertension and morphological pattern [59-67]. 
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Subsequently, a number of prognostic models integrating the different risk factors have 
been developed [4, 6, 60, 68-72]. They all aim to predict risk of ESRD but differ 
substantially in what risk factors are included. The Oxford classification of IgAN [4] is a 
prognostic system that is primarily based on the morphological picture, and this system is 
validated and found applicable also in other patient cohorts [73-77].  A recently published 
French prognostic system is based on the presence or absence of hypertension and 
proteinuria above 1 gram/24 hours together with the morphological picture, this system 
has not yet been validated in other IgAN groups [68]. Finally, a Japanese system is based 
primarily on clinical risk factors with the morphological picture playing only a minor role, 
[6],  validation of this system is a part of the present thesis and is specifically addressed in 
paper II.     
 
Most IgAN patients are treated with blood pressure lowering agents including ACE 
inhibitors or ARB´s [78-80]. Some, but not all studies, have demonstrated a beneficial 
effect of omega 3 fatty chains [81-83]. In a number of relatively small studies, a beneficial 
effect of steroids on progressive cases of IgAN is demonstrated. However, large 
randomized controlled studies confirming these findings have so far unfortunately not 
been performed [3, 84-95]. Generally, long lasting and high dose steroid courses are 
causing serious side effects and such treatment should be restricted to IgAN patients with 
high risk of progressive disease [1, 3]. Prognostic tools to identify patients suitable for 
aggressive treatment are therefore very useful.  
 
Despite active treatment, many IgAN patients develop ESRD, and for such patients 
kidney transplantation is the preferred treatment modality [33-35]. As IgAN can be 
considered as a systemic disease which affects the kidneys, it is not surprising that it often 
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recurs in the transplanted kidney [2]. On the other side, when kidneys with IgA 
depositions [58] are used for donation to non IgAN  recipients, these depositions tend to 
disappear spontaneously [96]. IgAN is usually a slowly evolving condition and the post-
transplant immunosuppressive treatment may further slow development of recurrent 
disease. Thus, recurrent IgAN rarely causes graft loss before long time after 
transplantation [97-103]. A rapid course of IgAN with crescents that has re-occurred in 
the transplanted kidney and caused graft loss has been described in a few casuistic reports 
[104-106]. Except for these few reports, little is known about the relationship between the 
initial disease presentation and course of IgAN before ESRD and the outcome after 
subsequent kidney transplantation. This issue is the topic addressed in paper III of the 
present thesis.     
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AIMS OF INVESTIGATION 
 
I. To study whether patients with established membranous nephropathy has an increased 
long-term risk of cancer compared to the age and gender adjusted general population. 
II. To study whether a new  Japanese scoring system to quantitatively predict risk of 
ESRD after 10 years of disease duration in IgA nephropathy is valid also in 
Norwegian patients.   
III. To study whether the initial clinical and histopathological presentation and course of 
disease prior to ESRD are risk factors for graft loss after kidney transplantation in IgA 
nephropathy patients. 
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REGISTRIES USED IN THE THESIS 
The Norwegian Kidney Biopsy Registry 
The Norwegian Kidney Biopsy Registry is located at Haukeland University Hospital, was 
established in 1988 and has registered clinical, biochemical, immunological and 
morphological data from most patients who have had a kidney biopsy performed in Norway 
since 1988. All kidney biopsies are evaluated by an experienced nephropathologist at the 
Gade Institute at Haukeland University Hospital in Bergen. 
 
The Norwegian Renal Registry 
The Norwegian Renal Registry is located at Oslo University Hospital Rikshospitalet, was 
established in 1980 and has registered cause of ESRD, date of commencement of renal 
replacement therapy (RRT), switch of RRT modality, follow up data on RRT patients 
including major co morbidities and causes of death on all patients established in RRT in 
Norway. 
 
The Norwegian Cancer Registry 
The Norwegian Cancer Registry is located in Oslo and was established in 1953. Registration 
of cancers in Norway has been based on compulsory reporting of cancer cases by hospital 
departments, histopathological laboratories and death certificates from Statistics Norway. The 
completeness of data is documented to be 98-99 % for solid tumors [107, 108]. The complete 
cancer epidemiologic information in the registry allows calculation of a reliable and accurate 
estimate of the expected number of cancers and identification of all observed cancer cases in 
any given cohort. 
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The Population Registry of Norway 
The Population Registry is a part of the tax office in Norway and deaths among 
Norwegian citizens are registered on a weekly basis. Data from this registry includes 
whether a person is alive or not, and if the person is dead, date of death is available.
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IDENTIFICATION OF PATIENT COHORTS AND THEIR 
CHARACTERISTICS
Paper I 
Patients were included based on a search in the Kidney Biopsy Registry for MN and 
registered proteinuria. Patients registered between start of the registry in 1988 and the end of 
2003 was included. Secondary causes of MN in the cohort were identified through registry 
information and clinical information on the pathology form. Clinical and morphological data 
were obtained from the Kidney Biopsy Registry and included; age in years, gender,  eGFR 
(ml/min/1.73m2), s-albumin (g/dl), proteinuria (g/24 hours), systolic and diastolic blood 
pressure (mmHg), degree of nephron loss (0-3), glomerular sclerosis (0-3), interstitial 
inflammation (none, acute or chronic), chronic interstitial fibrosis (0-3) and glomerular 
immunodeposits (none, focal, diffuse) of immunoglobulin (Ig) IgA, IgG, IgM, complement 
factor 3 (C3) and C1q. 
 
Paper II 
The study cohort in paper II was identified by a search in the Kidney Biopsy Registry for 
patients with IgAN registered between start of the registry in 1988 and the end of 2004. Data 
necessary for calculation of ESRD risk, as defined in the Japanese scoring system for IgAN, 
were obtained from the Kidney Biopsy Registry and included eGFR (ml/min/1.73m2), 
proteinuria (dipstick or quantitative  measure methods), systolic blood pressure (mmHg), 
serum albumin (g/l), hematuria (dipstick), morphology (presence or absence of; 
glomerulosclerosis, crescents or adhesions to Bowmanns capsule in more than 10 % of 
glomeruli and/or prominent changes in interstitium and/or blood vessels), gender and age.  
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Paper III 
A search in the Kidney Biopsy Registry for patients with IgAN registered between start of the 
registry in 1988 and the end of 2004 were made and those identified were linked to the Renal 
Registry. The study cohort consists of those who had received a kidney transplant by the end 
of 2006.  
Clinical and morphological data were obtained from the Kidney Biopsy Registry and 
included; age (years), gender, estimated GFR (MDRD formula) (ml/min/1.73m2), proteinuria 
(more or less than 1 g/l), systolic and diastolic blood pressure (mmHg), morphologically 
grade 1-2 or 3-4 according to the Japanese histology grading system for IgAN.  
By combining data from the Kidney Biopsy Registry and the Renal Registry time from 
diagnosis of IgAN to ESRD (years) and mean annual loss of GFR (¨GFR) 
(ml/min/1.73m2/year) were calculated. ¨GFR = (initial GFR minus residual GFR at initiation 
of ESRD) divided by time between diagnosis of IgAN and commencement of RRT. As we 
did not have data on residual GFR at initiation of RRT, this was set to 5 ml/min/1.73m2.  
Data that could be of significance for graft outcomes were obtained from the Renal Registry 
and included donor source, donor age, donor gender, recipient age below 30 years, pre-
emptive transplantations, the presence of panel reactive antibodies (PRA), number of HLA 
A/B/DR mismatches, the presence of tissue type HLA B8DR3 in recipients and the post-
transplant immunosuppressive regimen.  
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Definition of observation periods, sources and characteristics of outcome 
data and definitions of primary endpoints 
Paper I 
The observation period of patients was defined as the time between the kidney biopsy and 
diagnosed cancer, end of 2003 or death whichever came first. Outcome data were obtained 
through record linkage of the study cohort with the Cancer Registry. All diagnosed cases of 
cancer, including information regarding subtype of cancer, in the study cohort were 
registered. The primary endpoint of this study was the standardized incidence rate (SIR) of 
cancer after MN diagnosis. 
Paper II 
The observation period of patients was defined as the time between diagnoses of IgAN and 
ESRD, end of 2008 or death whichever came first. Data regarding development of ESRD, 
which also was the primary endpoint of the study, was obtained from the Renal Registry.  
Paper III 
The observation period of patients was defined as the time between kidney transplantation and 
end of 2008, death or graft loss whichever came first. Outcome data was obtained from the 
Nephrology Registry and included steroid-sensitive acute rejection, steroid-resistant acute 
rejection and non-immunologic complications (ureter, vascular, wound/lymphocele, delayed 
graft function and infections) the first three months after transplantation. GFR one year post 
transplant and at the last follow up registration, graft loss, histologically verified recurrence of 
IgAN, retransplantations, deaths, deaths with functioning graft and cause of death were also 
obtained from the Nephrology Registry. 
The primary endpoint was graft loss. Death with functioning graft was treated as a censoring 
event.    
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STATISTICAL METHODS AND ANALYSES  
 
In simple comparisons (all papers), independent samples t-test was used for test of statistical 
significance in normally distributed continuous variables, Mann-Whitney test for not normally 
distributed continuous variables and Chi-square test for categorical variables. 
In all papers, Kaplan Meier statistics and survival curves were used and log rank test was used 
for test of statistically significance of differences between the compared groups. In paper I the 
cumulative risk of cancer in the complete cohort, and in patients older versus younger than 60 
years was illustrated. In paper II, the cumulative risk of ESRD in 9 risk groups were 
calculated and compared and the data was also used to create a simplified prognostic system 
with 5 risk groups. This was done by merging of risk groups that were not statistically 
different from each other when compared with log rank test. We also used the KM method to 
compare risk of pre-ESRD deaths between these 5 risk groups. In paper III, the KM method 
was used to compare graft survival between patients with rapid versus slow progression of 
IgAN as well as between patients with transplanted kidneys from living related versus (LRD) 
unrelated donors (UD).  
In paper I, standardized incidence ratio (SIR) of cancer was calculated in a two-step manner. 
First, the expected number of cancer in the study group was calculated based on national 
cancer rate data adjusted for gender, age in 5 year intervals and time period in 5 year intervals. 
Second, SIR was calculated as the observed divided with the expected number of cancers in 
the study cohort.      
In paper II, Cox regression statistics was used to analyse unadjusted and adjusted hazard 
ratios (HR) of the 8 prognostic elements in the Japanese prognostic system for IgAN. 
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In paper III, we converted the continuous variable ¨GFR into a dichotomous categorical 
variable named slow progression (SP) or rapid progression (RP) of IgAN. To identify the 
optimal definition of RP and SP of IgAN, we tested different cutoffs for ¨GFR (10, 20, 30, 
40, and 50 ml/min/1.73m2/year) in an adjusted Cox regression model and chose the definition 
that best separated RP and SP patients. We also used Cox regression statistics to compare risk 
of graft loss between RP versus SP patients with IgAN in a model with adjustment for 
possible confounders.     
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SUMMARY OF MAIN RESULTS 
Paper I 
One hundred sixty-one patients with MN were identified. Fifteen patients had MN secondary 
a non-malignant cause. Cancer was diagnosed in 33 patients, 9 before and 24 after diagnosis 
of MN. 
The mean annual incidence rate of cancer after MN was 2.4/100 person-years, 2.1/100 
person-years 0-5 years after MN and 2.8/100 person years 5-15 years after MN diagnosis. 
SIR of cancer in the cohort after MN diagnosis was 2.3 (95 % CI, 1.4 - 3.4) after exclusion of 
secondary cases including those with cancer prior to MN, SIR of cancer was 2.3 (95 % CI, 1.5 
– 3.5). SIR of cancer in male patients with MN was 2.1 (95 % CI, 1.3 – 3.4) and in female 
MN patients 2.5 (95 % CI, 1.0 – 5.2). SIR of cancer 0 – 5 years after MN was 2.2 (95 % CI, 
1.1 – 3.9) and 2.3 (95 % CI, 1.2 – 4.0) 5 – 15 years after diagnosis of MN. The only single site 
cancer with a significantly increased SIR was prostate cancer (SIR 2.9, 95 % CI 1.1 – 6.4).  
After exclusion of the 3 cases with cancer diagnosed less than 6 months after MN, SIR of 
cancer was 2.1 (95 % CI, 1.3 – 3.2). After 15 years of follow up the cumulative risk of cancer 
was 34 %, 57 % in patients older than 60 years and 19 % in patients younger than 60 years. 
 
Paper II 
A total of 633 patients were identified and 146 of these developed ESRD, 121 after less than 
10 years of follow up. Forty-five patients died before they reached ESRD. 
The observed 10 year cumulative risk of ESRD was within or close to the expected range in 8 
of 9 risk groups covering 94% of the cohort. The much lower than expected 10 year risk of 
ESRD in risk group 8 is partly explained by many pre-ESRD deaths among these patients.  
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The observed ESRD risk 15-17.5 years after diagnosis of IgAN substantially exceeded the 
predicted and observed 10 year risk in risk groups 3-5 (predicted 5-30 % risk). The 
cumulative risk of pre-ESRD deaths increased with increasing risk of ESRD. After merging 
of risk groups that did not have significantly different  prognosis, 5 risk groups appeared with  
0-5 %, 5-10 %, 10-50 %, 50-90 % and >  90% 10 year risk of ESRD. All components of the 
scoring system, except male gender, were associated with an increased risk of ESRD, also in 
an adjusted model. The HR of pre-ESRD deaths was 3.0 in patients with an initial eGFR < 60 
ml/min/1.73m2 after adjustment for age and gender.     
 
Paper III 
One hundred six transplanted IgAN patients were identified. There were 14 patients with graft 
loss. Patients with versus without graft loss had higher ¨GFR (38 ± 40 versus 12 ± 17 
ml/min/1.73m2/year, p=0.02) and shorter time from diagnosis of IgAN to ESRD (2.9 ± 2.8 
versus 5.1 ± 4.3 years, p=0.048). The highest adjusted HR (6.0, 95 % CI 1.6 – 22) associated 
with being a rapid progressive IgAN patient was observed with a definition of RP as ¨GFR > 
30 ml/min/1.73m2/year. At time of transplantation, RP patients were younger (30 ± 10 versus 
46 ± 14 years, p<0.001) and a higher proportion received a LRD graft (82 % versus 42 %, 
p=0.01) than SP patients with IgAN. After transplantation, RP patients tended to have more 
morphologically verified  recurrence of IgAN (18 % versus 5 %) than SP patients but this 
difference was not statistical significant. The only major difference in outcome was graft loss, 
55 % in RP versus 8 % in SP patients (p>0.001). The unadjusted HR for graft loss in RP 
versus SP patients was 4.5 (95 % CI, 1.5 - 14). After adjustment for donor age, donor gender, 
HLA mismatches, PRA status, HLAB8DR3 status, pre-emptive transplantation, type of 
immunosuppressive regimen, LRD and recipient age < 30 years the HR of raft loss with RP 
versus SP increased to 12.8 (95 % CI, 2.2 – 74).  
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GENERAL DISCUSSION 
Valid knowledge regarding prognostic factors and outcomes in patients with primary 
glomerulonephritides is of importance in clinical practise and has thus been the principal aim 
of the studies in the present PhD thesis. In paper I, we described a substantial increased risk of 
cancer in MN patients that was not, as suggested by previous reports [39, 40], limited to a 
short time period around the debut of the renal disease. As discussed in the paper, we do 
believe that tumors that at the time of diagnosis are clinically undetectable but 
immunologically active and  the use of immunosuppressive drugs are the two most probable 
explanations of our findings. The fact that immunosuppressive drugs are associated with an 
increased risk of cancer underscores the importance of restricting the use of such drugs to 
patients with progressive disease only. Thus, the study of prognostic factors and the 
combination of such factors into prognostic systems is of clinical importance in the guidance 
of appropriate therapy. In paper II, we evaluated a recently published Japanese prognostic 
system for IgAN [6] and found it applicable also in Norwegian patients. With this prognostic 
tool, a large fraction of IgAN patients with a benign prognosis could be identified and these 
patients should not receive toxic drugs. Although the principal aim of treating CPGN patients 
is to avoid progression to ESRD, this goal cannot always be achieved with the treatment 
options currently available. For such patients, the optimal treatment option is kidney 
transplantation. Although the results of kidney transplantation generally are excellent, 
recurrence of CPGN sometimes leading to graft failure is a clinically significant concern [2].  
In paper III, we investigated to what extent the presentation and course of IgAN in the native 
kidneys was associated with graft survival after kidney transplantation. An important finding 
was that those patients with a particularly rapid course of IgAN, defined as mean annual loss 
of GFR exceeding 30 ml/min/1.73m2 had a much higher risk of graft loss after kidney 
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transplantation. As we to date have no effective therapy against aggressive IgAN, neither 
before nor after transplantation, the current clinical impact of this finding is limited. On the 
other hand, it is noteworthy that among slow progressive IgAN patients, the risk of graft loss 
as well as risk of death with functioning graft is low, demonstrating that kidney 
transplantation is an excellent treatment option in such patients.  
 
Cancer as an underlying cause of glomerulonephritides is fairly well documented among MN 
patients [37-42, 44, 45] but also, although less frequently, in patients with other glomerular 
diseases; most known of which is probably minimal change disease secondary to Hodgkin 
lymphoma [43, 109]. Long-term risk of cancer in primary glomerulonephritides patients is 
however much less well studied. To our knowledge, only one well-performed and population 
based study except ours has been published [7]. In this Danish study, using linkage of a 
kidney biopsy registry with a national cancer registry, generally the same observations 
regarding MN and cancer as we found, was reported. Of interest, in this study, an increased 
long-term risk of cancer was also reported in most other types of primary 
glomerulonephritides. This finding indicates a common risk factor for cancer in CPGN 
patients, the use of immunosuppressive drugs being the most likely one. The fact that the most 
commonly used types of immunosuppressive drugs in CPGN patients, cyclophosphamid and 
cyclosporin, are associated with an increased risk of cancer also in other patient groups [10, 
11], supporting a similar explanation of the observations in the Danish study. When 
considering the clinical importance of the observed increased long term risk of cancer in MN, 
it is useful both to consider the relative and absolute risk increase. In our study, the 
cumulative risk of cancer among MN patients older than 60 years after 10 years of follow up 
was close to 60 %, much higher than the expected number of less than 30 %. When also taken 
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into account that most MN patients who were diagnosed with cancer died during follow up, 
our finding is undoubtedly of major clinical significance.  
    
Many patients with primary glomerulonehritides, particularly IgAN and MN patients, have a 
benign prognosis regarding risk of ESRD also without treatment with immunosuppressive 
drugs [59]. Thus, prognostic tools to identify such patients are of importance to avoid 
potentially dangerous over-treatment with toxic drugs. In MN, a Canadian prognostic system 
was published many years ago [110]. This system has later been validated and found 
applicable also in MN populations from Finland and Italy [5]. However, it can be anticipated 
that new prognostic systems in MN will be suggested that includes serial titres of PLA2R auto 
antibodies when these becomes generally available. In IgAN, a well-accepted and validated 
prognostic system has been lacking and a number of different models have been suggested 
during the last few years [4, 6, 68]. They differ substantially in what prognostic factors are 
included, particularly regarding the importance of the histological picture. In paper II we 
conclude that a Japanese prognostic system [6] is applicable to predict 10 year risk of ESRD 
also in Norwegian IgAN patients. Despite this conclusion, we are not convinced that the 
Japanese system will become generally accepted as the optimal prognostic tool in IgAN. An 
ideal prognostic tool in IgAN should probably include a longer observation period than 10 
years, deaths occurring in patients with progressive disease should be included as an end-
point and expected time from diagnosis of IgAN to ESRD should also be included in the 
prediction. Our data indicate that eGFR, proteinuria, blood pressure and the histological 
picture are the most important independent risk factors for ESRD in IgAN patients and that a 
future prognostic scoring system therefore probably should be based primarily on these. 
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Recurrence of the initial disease in transplanted kidneys is observed with all subtypes of 
primary glomerulonephritides [2]. Graft loss due to recurrent disease is most often observed 
in patients with focal and segmental glomerulosclerosis (FSGS), in such patients it may occur 
shortly after transplantation [111]. In IgAN, graft loss due to recurrence is also commonly 
observed but usually occurs long time after transplantation [97-103]. In MN, recurrence is 
common after transplantation but it rarely causes graft loss [24]. In paper III we showed that a 
rapidly progressive course of IgAN, mostly seen in young patients, is associated with a 
substantially increased risk of graft loss. Young age and aggressive initial disease presentation 
are also associated with increased risk of recurrence and graft loss in FSGS patients [24]. 
 
There are some important strengths of the studies in the present thesis; first, they are all 
population based and thus, selection bias is avoided. Second, the cohorts are fairly large and 
with a long follow up time. Third, the major end-points (cancer, ESRD and graft loss) are all 
well-defined and clinically relevant. Fourth, end-points occurring in the study cohort have 
been identified from high quality national registries, a method that secures a valid and 
complete registration of the outcome parameters. 
  
Some methodological weaknesses of our study must also be admitted. First and most 
importantly, we did not have information regarding disease evolvement and treatment 
between diagnosis of MN / IgAN and occurrence of cancer or ESRD. Such data would have 
been of interest regarding the understanding of causes and mechanisms of our findings. 
Information regarding the association between PLA2R auto-antibodies and idiopathic MN 
became known after paper I had been published. If the use of immunosuppressive drugs and 
PLA2R antibody status among patients in the study cohort of paper I had been known the 
following two subgroup analyses would have been very interesting to perform; 
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1. Long-term risk of cancer in PLA2R negative idiopathic MN patients. 
2. Long-term risk of cancer in PLA2R positive MN patients who have received 
immunosuppressive drugs.  
In paper III, we did have some information regarding treatment and course between kidney 
transplantation and graft loss of our patients but available information regarding recurrence of 
IgAN was scarce, due too few post-transplant biopsies.  
 
In summary, the major clinical and prognostic implications of the findings in the present PhD 
thesis are; in particularly older MN patients, the possibility of an underlying cancer should be 
carefully investigated. If a tumor is not detected initially, it should be looked for also during 
the follow up period. Due to increased risk of cancer in MN, immunosuppressive drugs 
should only be used in patients with a high risk for ESRD. The Japanese prognostic scoring 
system for IgAN is applicable to predict 10 year risk of ESRD also in Norwegian patients. 
Patients with a predicted risk between 5 and 30 % are most likely to develop ESRD after more 
than 10 years of follow up.  Progressive IgAN is associated with an increased all-cause 
mortality rate. Patients with a rapidly progressive course of IgAN (¨GFR > 30 
ml/min/1.73m2) have a much higher risk of graft loss after transplantation than other IgAN 
patients.      
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CONCLUSIONS 
First, we have demonstrated that the risk of cancer is substantially elevated for many years of 
the follow up period after MN diagnosis, as opposed to previous reports that had indicated 
that the increased risk of cancer was limited to one year before and after MN diagnosis. 
Second, we have documented that a recently published Japanese scoring system aimed at 
predicting 10 year risk of ESRD in IgAN patients also is applicable in Norwegian patients. 
Furthermore,  this scoring system could be used to identify those patients at highest risk of 
pre-ESRD deaths and also those at highest risk of developing ESRD after more than 10 years 
of disease duration. 
Third, we have shown that IgAN patients experiencing a rapid loss of renal function in their 
native kidneys have a greatly increased risk of graft loss after transplantation compared to 
other IgAN patients.  
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